2-DG- A New Ray of Hope! Developed By DRDO to Battle Corona Menace.
2-DG, (2-deoxy-D-glucose ) is a new anti-COVID drug to boost the fight against COVID-19.
Dr. Swapnil B Mantri
(Pediatrician and Nutritionist)
Samaj Vikas Samvad
Mumbai,
2-DG- A New Ray of Hope! Developed By DRDO to Battle Corona Menace, The DRDO previously explored 2-DG as an anti-cancer therapy, INMAS-DRDO scientists conducted a successful laboratory experiment of 2DG.
2-DG, (2-deoxy-D-glucose ) is a new anti-COVID drug to boost the fight against COVID-19.
DRDO indigenously researched developed & launched 2-deoxy-D-glucose (2-DG) to fight COVID.
by Defence Minister Rajnath Singh and the Union Health Minister Dr. Harsh Vardhan.
Defense Research and Development Organisation released The first batch comprising more than 10,000 doses.
Institute of Nuclear Medicine and Allied Sciences and Dr. Reddy’s Laboratories, Hyderabad.
The drug has gone through three phases of clinical trials.
Published data for the trials is not yet available; however,
as per the Ministry of Defence press release dated 8th May 2021,
Clinical trial results have shown that this molecule helps in the faster recovery of hospitalized patients and reduces supplemental oxygen dependence.
The higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients.
INMAS-DRDO scientists conducted a successful laboratory experiment of 2DG.
INMAS-DRDO scientists conducted laboratory experiments with the help of the Centre for Cellular and Molecular Biology, Hyderabad,
and found that this molecule works effectively against the SARS-CoV-2 virus and inhibits viral growth.
The developers conducted phase II-A trials in six hospitals with satisfactory results, subsequently,
The DRDO also undertook the Phase II-B trials for critical clinical trials in 11 more hospitals,
in which the patients showed significant improvement.
A total of 110 patients participated in The phase II trial.
Inefficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints.
A significantly favorable trend was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SoC.
The Phase-III clinical trial was conducted on 220 patients between December 2020 to March 2021 at 27 COVID hospitals in
Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka, and Tamil Nadu.
DRDO presented The detailed data of the phase-III clinical trial to DCGI.
2-DG- A New Ray of Hope! Developed By DRDO to Battle Corona Menace.
In the 2-DG arm, a significantly higher proportion of patients improved symptomatically
and became free from supplemental oxygen dependence (42% vs 31%) by Day-3 in comparison to SoC,
indicating an early relief from Oxygen therapy.
A similar trend was observed in patients aged more than 65 years.
Salient features of 2-DG or, 2-deoxy-d-glucose.
Salient features of 2-DG or, 2-deoxy-d-glucose.
Glucose analog
- Indication: DCGI approved for emergency use as an adjunct therapy in moderate-to-severe COVID-19 cases.
- Formulation: Sachet is taken orally by dissolving it in water for 5-7 days as reported.
- Mechanism of action: A unique characteristic of this drug is its selective accumulation in virally infected cells.
By accumulating in the virus-infected cells, it prevents virus growth by stopping viral synthesis and energy production.
The DRDO previously explored 2-DG as an anti-cancer therapy.
2-DG- A New Ray of Hope! Developed By DRDO to Battle Corona Menace.
The DRDO previously explored 2-DG as an anti-cancer therapy.
The ability of 2-deoxy-d-glucose (2-DG) to interfere with d-glucose metabolism demonstrates that nutrient and
energy deprivation is an efficient tool to suppress cancer cell growth and survival.
Acting as a d-glucose mimic, 2-DG inhibits glycolysis due to the formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P),
inhibiting the function of hexokinase and glucose-6-phosphate isomerase, and inducing cell death.
The ongoing second pandemic wave has created a huge demand for oxygen; hence,
this drug has come at an opportune time. By reducing oxygen demand,
it will reduce hospitalization.
The cost of this drug is not yet determined,
but we hope that it would be affordable so that it is accessible to the large majority of people and thus help save precious lives.
…
2-DG, 2-deoxy-D-glucose, COVID-19, anti-COVID drug, anti-cancer therapy,
2-deoxy-d-glucose-6-phosphate (2-DG6P), laboratory experiment of 2DG,
Ayurveda, Indian-rail, economy, gadgets, science-technology,
समाज, समाज विकास, समाज संवाद, विकास, विकास संवाद, संवाद,
samaj, samaj vikas, samaj samvad, vikas, vikas samvad, samvad,
[…] व्यापार संवाद, आयुर्वेद संवाद, गैजेट्स संवाद, समाज विकास संवाद […]
[…] अलावा पी एम ने आयुष्मान भारत योजना (Ayushman Bharat Yojana) के तहत […]
[…] By, Somen M. […]